COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Submitted, not yet approved
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Task sharing management of non-communicable diseases using mobile health in rural India
Scientific title
Effectiveness of a package of lifestyle intervention, delivered by community health workers, to control non-communicable diseases in rural India: A cluster randomised controlled trial
Secondary ID [1] 300682 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertension 316486 0
Diabetes 316487 0
Pre-diabetes 316525 0
Anaemia 316526 0
Hyperlipidaemia 316527 0
Obesity 316528 0
Condition category
Condition code
Cardiovascular 314737 314737 0 0
Public Health 314738 314738 0 0
Health promotion/education
Public Health 314739 314739 0 0
Other public health
Cardiovascular 314928 314928 0 0
Other cardiovascular diseases
Metabolic and Endocrine 314929 314929 0 0
Blood 314930 314930 0 0
Diet and Nutrition 314931 314931 0 0

Study type
Description of intervention(s) / exposure
The intervention group will receive two main components of the intervention. The overall duration of the intervention will be 12 months (Step A for 3-month and step B for 9-month). The first 3 months will involve Step A and step B will begin immediately on completion of step A.

Step A: Group-based education will be delivered by an Accredited Social Health Activist (ASHA) focusing on various aspects of knowledge to manage hypertension and comorbid conditions fortnightly up to three months (six meeting sessions). She will perform a routine check-up and provide health education to all enrolled participants living in her village. Step A will be conducted in the community hall.
Each meeting session will consist of two activities. Firstly, the ASHA will measure blood pressure (BP), heart rate, and weight of the participants. The ASHA will also inquire about their last visit to the health and wellness centre for managing hypertension and assess their current adherence to prescribed medications. The ASHA will use a tablet device (The Arogya Sahyog application) to store these data and let the participant know how s/he is doing with regard to management of blood pressure. Secondly, she will conduct group-based education sessions. The sessions will last for ~ 90 minutes and include the following activities.
• Introduction: ASHAs will teach participants about risk factors, their consequences, and management
• Self-management education: ASHAs will advise the participants on dietary changes and adherence to medications.
• Physical activity: ASHAs will instruct the participants to increase their physical activity. ASHAs will also advise on the type, frequency, and intensity of various exercises that can help them to reduce weight and keep healthy.
• Nutrition and diet: ASHAs will advise the participants to eat more grains, vegetables, fruits, and reduce consumption of salt, sugar, and alcohol.
• Practical self-management: ASHAs will implement SMART (Specific, Measurable, Attainable, Relevant, Timely) goal-setting and monitor the progress of the participants to support the self-management of risk factors.

Step B: The ASHA will visit participants' homes for providing 3-monthly monitoring of BP and risk factors for nine months. This will be one-on-one monitoring activity. Each 3-monthly visit will include monitoring targets for BP and other relevant risk factors, adherence to medication, and providing one-on-one self-management support. These tasks are simplified for the ASHA with the use of the simple management and referral algorithm built within the tablet device. When risk factors are poorly controlled at each visit, the ASHA will refer patients to a health and wellness centre. Each participant will be visited with the ASHA for ~ 30 minutes.
Intervention code [1] 317008 0
Intervention code [2] 317009 0
Comparator / control treatment
The ASHA will inform all participants about their risk and advise them to visit the nearest primary health centre for receiving the usual care. The ASHA will provide no further interaction.
In a routine system, medical doctors are responsible for providing treatment of hypertension and management of other complications (co-morbidities) in primary health centres. Doctors also provide follow up advice to patients.
Control group

Primary outcome [1] 323087 0
The primary outcome is a between-group change of systolic blood pressure between baseline and 12 months

Timepoint [1] 323087 0
One year after randomisation (ASHAs will use sphygmomanometer for collecting data on tablet devices)
Secondary outcome [1] 380743 0
Between-group differences in control of hypertension, i.e. blood pressure less than 140/90 mmHg
Timepoint [1] 380743 0
Three months and one year after randomisation (ASHAs will use sphygmomanometer for collecting data on tablet devices)
Secondary outcome [2] 380869 0
Between-group differences in adherence to treatment
Timepoint [2] 380869 0
Three months and one year after randomisation (ASHAs will use a standard questionnaire for collecting data on tablet devices. The questionnaire was designed specifically for this study)
Secondary outcome [3] 380958 0
Changes of knowledge on health literacy among people with hypertension with or without co-morbidities (diabetes, pre-diabetes, anaemia, and hyperlipidaemia)
Timepoint [3] 380958 0
Three months and one year after randomisation (ASHAs will use the Health Literacy Questionnaire for collecting data on tablet devices)
Secondary outcome [4] 381025 0
Acceptability of using ASHAs to manage hypertension and vascular risk factors
Timepoint [4] 381025 0
One year after randomisation (In-depth interview guideline will be used for collecting information related to acceptability among ASHAs)
Secondary outcome [5] 381026 0
Perceptions of patients about the type and availability of support they received from ASHAs
Timepoint [5] 381026 0
One year after randomisation (In-depth interview guideline will be used for ASHA supervisors and auxiliary nurse midwives collecting information)

Key inclusion criteria
1. Participants aged 30 years and above
2. Systolic blood pressure greater than 139 mmHg and/or diastolic arterial pressure greater than 89 mmHg or prescription of antihypertensive medications.

Minimum age
30 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Critical patients who require immediate referral to a tertiary care facility
2. Patients with vision or hearing impairments
3. Patients who do not intend to stay in the study catchment area for one year

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is concealed by central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Other design features
Pre-intervention screening to select eligible participants:
ASHAs will use an mHealth app, 'Arogya Sahyog' installed on a tablet a device, to screen the participants. The screening will comprise:
Part 1: Identification of people with hypertension, and co-morbidities (diabetes, pre-diabetes, anaemia, and hyperlipidaemia) in those with hypertension, using standardised assessments.
Part 2: Establishing diagnostic accuracy and ascertaining risk.
In those with a confirmed diagnosis of hypertension, all participants will be informed about their risk and advised to visit a health centre.

Qualitative interviews:
We will conduct 3-4 in-depth interviews with (i) clinicians and Auxiliary Nurse Midwives (ANM) to determine the acceptability of using ASHAs to manage hypertension and vascular risk factors, and the impact of the new approach on their workload, (ii) ASHAs to determine acceptability of the approach to them and their workload in managing NCDs

3-month and 12-month assessments undertaken by the research team:
At the end of the 3-month and 12-month intervention, we will re-assess BP and other vascular risk factors in both the intervention and usual care groups using independent research team members who are unaware of the group allocation.

We will undertake a process evaluation to determine factors such as (i) adherence to referral pathways in line with the algorithm in the tablet device, (ii) the type/availability of support received by participants from ASHAs, (iii) assessing patients’ perceptions of the support they received from ASHAs.
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
Efficacy of the intervention, e.g. systolic blood pressure (SBP) at follow-up, will be adjusted for baseline levels, by using a mixed-effect regression analysis (clustered by village). All analyses will be based on intention-to-treat. Generalised Estimating Equations (GEE) will be used to study the factors associated with control of hypertension and treatment. The scales of the continuous covariates will be checked for suitability using fractional polynomial plots. Collinearity between variables will be evaluated using partial correlations. In addition, routine diagnostic tests (Hosmer-Lemeshow test) will be used to validate the fitted models.
A content analysis approach will be adopted to analyse qualitative data. All the interviews and field notes from all in-depth interviews will be recorded and transcribed verbatim. A master code-list will be generated, based on which the rest of the transcripts will be coded. We will use NVivo qualitative data analysis software (QSR International Pty Ltd. Version 12, 2018).

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 22406 0
State/province [1] 22406 0

Funding & Sponsors
Funding source category [1] 305156 0
Name [1] 305156 0
Monash University
Address [1] 305156 0
Wellington Road
Clayton 3800
Country [1] 305156 0
Primary sponsor type
Monash University
Wellington Road
Clayton 3800
Secondary sponsor category [1] 305518 0
Name [1] 305518 0
Address [1] 305518 0
Country [1] 305518 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 305523 0
Garwhal Community Development and Welfare Society Chamba
Ethics committee address [1] 305523 0
Garhwal Community Development & Welfare Society
Christian Hospital, Chamba, Tehri Garhwal, Uttarakhand, India
PIN- 249145
Ethics committee country [1] 305523 0
Date submitted for ethics approval [1] 305523 0
Approval date [1] 305523 0
Ethics approval number [1] 305523 0

Brief summary
Accredited Social Health Activists (ASHAs), who are female community health workers in India, may be used to screen populations for hypertension, prediabetes, diabetes and cancer. These ASHAs will identify and refer cases to sub centres. First, they will complete a community-based assessment checklist for males and females aged 30 years and above. To enable ASHAs to be supported when they are on their own in the community, we have developed a mobile health (mHealth) application 'Arogya Sahyog' [in Hindi 'Health Assistant'} to be installed on a tablet. This mHealth app is designed to help ASHAs to screen, provide lifestyle advice, and refer critical patients to primary care physicians. We will teach ASHAs about NCDs so that they can motivate people to adhere to healthy lifestyle activities. We will also test whether this training programme improves ASHAs knowledge of NCDs. We will further randomise an equal number of ASHAs to either the intervention group or usual care group using a cluster randomised controlled trial (cRCT) design. Participants in the intervention group will receive a fortnightly group-based educational intervention for three months, followed by three-monthly monitoring support for 12 months. The outcome in this group will be compared to those receiving usual care. This will enable us to test whether mobilising this ASHA workforce results in better management of hypertension and diabetes in a rural area of India. We will further evaluate ASHAs capacity to provide health promotional interventions to patients with, or at risk of, NCDs using the tablet device.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 100562 0
Prof Amanda Thrift
Address 100562 0
Department of Medicine,
School of Clinical Sciences at Monash Health, Monash University
Clayton, VIC 3168, Melbourne, Australia
Country 100562 0
Phone 100562 0
Fax 100562 0
Email 100562 0
Contact person for public queries
Name 100563 0
Dr Sojib Bin Zaman
Address 100563 0
Department of Medicine,
School of Clinical Sciences at Monash Health, Monash University
Clayton, VIC 3168, Melbourne, Australia
Country 100563 0
Phone 100563 0
+61 414026891
Fax 100563 0
Email 100563 0
Contact person for scientific queries
Name 100564 0
Prof Amanda Thrift
Address 100564 0
Department of Medicine,
School of Clinical Sciences at Monash Health, Monash University
Clayton, VIC 3168, Melbourne
Country 100564 0
Phone 100564 0
Fax 100564 0
Email 100564 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
What data in particular will be shared?
Individual participant data underlying published results only
When will data be available (start and end dates)?
Beginning 12 months and ending 5 years following main results publication
Available to whom?
Anyone who wishes to access it
Available for what types of analyses?
Only to achieve the aims in the approved proposal
How or where can data be obtained?
Access subject to approvals by Principal Investigator (
What supporting documents are/will be available?
No other documents available
Summary results
No Results